Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6.57 USD | 0.00% | -2.23% | -6.14% |
17/05 | HC Wainwright Adjusts Kala Pharmaceuticals Price Target to $18 From $21, Maintains Buy Rating | MT |
14/05 | KALA BIO, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.14% | 18.5M | |
+46.55% | 754B | |
+40.95% | 630B | |
-5.82% | 352B | |
+19.90% | 331B | |
+9.56% | 298B | |
+18.45% | 250B | |
+11.88% | 217B | |
-0.78% | 216B | |
+6.49% | 164B |
- Stock Market
- Equities
- KALA Stock
- News KALA BIO, Inc.
- Transcript : Kala Pharmaceuticals, Inc., Q1 2020 Earnings Call, May 07, 2020